Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Misses Expectations By $0.01 EPS

Scholar Rock (NASDAQ:SRRK) announced its earnings results on Thursday. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.01), FiscalAI reports. During the same period last year, the company earned ($0.67) EPS.

Here are the key takeaways from Scholar Rock’s conference call:

• FDA accepted Scholar Rock’s BLA for apitegromab to treat children and adults with SMA and assigned a PDUFA action date of September 30, 2026, creating a clear potential approval catalyst.
• The FDA completed an unannounced re‑inspection of the Catalent, Indiana fill–finish site and now has up to 90 days to classify the facility, leaving regulatory timing uncertainty that could affect approval pacing.
• Scholar Rock included a second U.S. fill–finish facility in the resubmitted BLA and reports that all required drug product from that site has been filed, with ample commercial supply expected in early Q3 ahead of the PDUFA date.
• The company exited Q1 with $480 million in cash and marketable securities, drew an additional $100 million from its debt facility and $98 million from ATM proceeds, and retains options (additional draw and PRV monetization) to further strengthen the balance sheet.
• Pipeline momentum continues with enrollment in the OPAL infant/toddler SMA study, a planned mid‑year start of the phase II FORGE trial in FSHD, encouraging subcutaneous apitegromab phase I data, and ongoing phase I dosing of SRK‑439.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded up $1.94 on Friday, reaching $48.39. 1,049,039 shares of the company’s stock were exchanged, compared to its average volume of 1,331,426. Scholar Rock has a twelve month low of $27.07 and a twelve month high of $51.63. The company has a fifty day moving average of $46.15 and a 200-day moving average of $43.00. The company has a market capitalization of $5.77 billion, a price-to-earnings ratio of -14.11 and a beta of 0.70. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41.

Insiders Place Their Bets

In related news, CFO Vikas Sinha sold 10,410 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the sale, the chief financial officer directly owned 619,856 shares in the company, valued at approximately $30,726,261.92. The trade was a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Keith Woods sold 10,220 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the transaction, the chief operating officer owned 620,055 shares in the company, valued at approximately $30,736,126.35. This trade represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 102,736 shares of company stock valued at $4,977,900 in the last quarter. Company insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently bought and sold shares of SRRK. Siren L.L.C. grew its stake in Scholar Rock by 17.0% during the fourth quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock worth $476,842,000 after buying an additional 1,575,008 shares in the last quarter. Wellington Management Group LLP increased its holdings in Scholar Rock by 26.7% in the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after buying an additional 1,213,541 shares during the period. State Street Corp raised its position in shares of Scholar Rock by 7.2% in the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after buying an additional 271,331 shares in the last quarter. Orbis Allan Gray Ltd lifted its holdings in shares of Scholar Rock by 1,034.5% during the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock worth $151,044,000 after acquiring an additional 3,126,677 shares during the period. Finally, Bellevue Group AG lifted its holdings in shares of Scholar Rock by 10.1% during the 3rd quarter. Bellevue Group AG now owns 3,244,537 shares of the company’s stock worth $120,827,000 after acquiring an additional 297,242 shares during the period. Institutional investors own 91.08% of the company’s stock.

Analyst Upgrades and Downgrades

SRRK has been the subject of several research reports. JPMorgan Chase & Co. raised their price objective on shares of Scholar Rock from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday, March 16th. Barclays increased their target price on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday. BMO Capital Markets lifted their price target on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Citigroup boosted their price target on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Finally, Truist Financial upped their price objective on Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Five research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $56.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).